Concepedia

Brett Wallden

BW

9

Publications

1.4K

Citations

9

H-Index

2005

Active since

Affiliations

Nanostring Technologies (United States)(Current)

University of Washington

Seattle University

BC Cancer Agency

Brett Wallden is an author at Nanostring Technologies (United States) specializing in tumor immunity, tumor biology, and pathology.

Top concepts

Publications per year

2005–2018

9

Publications

9

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Brett Wallden, James J. Storhoff, Torsten O. Nielsen et al. · BMC Medical Genomics · 2015 · 543 citations · Full text

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

Patrick Danaher, Sarah Warren, Rongze Lu et al. · Journal for ImmunoTherapy of Cancer · 2018 · 413 citations · Full text

, , +16

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Torsten O. Nielsen, Brett Wallden, Carl Schaper et al. · BMC Cancer · 2014 · 303 citations · Full text

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

Charlotte L. Tykjaer Jørgensen, Torsten O. Nielsen, Karsten Bjerre et al. · Acta Oncologica · 2013 · 32 citations · Full text

Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.

Brett Wallden, Irena Pekker, Simina Popa et al. · Journal of Clinical Oncology · 2016 · 18 citations

, , +30

Rows per page

1–5 of 9